Brief: Barinthus Bio Initiates Phase 1 Clinical Trial Of Vtp-1000 For The Treatment Of Celiac Disease
24/09/2024 13:28
Sept 24 (Reuters) - Barinthus Biotherapeutics PLC
2ABy.F :
* BARINTHUS BIO INITIATES PHASE 1 CLINICAL TRIAL OF VTP-1000
FOR
THE TREATMENT OF CELIAC DISEASE
* BARINTHUS BIOTHERAPEUTICS PLC - NO CURRENTLY APPROVED
TREATMENTS
FOR CELIAC DISEASE
Source text for Eikon: ID:nGNX7hNzSf
Further company coverage: 2ABy.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Barinthus Biotherapeutics
See all newsBrief: Barinthus Bio Provides Update On Proposed Combination With Clywedog Therapeutics
Brief: Barinthus Biotherapeutics PLC Appoints Douglas Swirsky As CFO And Principal Accounting Officer Effective May 1, 2026
Brief: Barinthus Bio Announces Update On Phase 1 AVALON Clinical Trial Of VTP-1000 For The Treatment Of Celiac Disease
Brief: Barinthus Bio Reports Second Quarter 2025 Financial Results And Updates On Corporate Developments
Gemma Brown Terminated As CFO Effective April 30, 2025 - SEC Filing